Acknowledgments. The authors thank the study volunteers who contributed time to this study.

Funding. This trial was funded by the Leona M. and Harry B. Helmsley Charitable Trust and JDRF International (3-SRA-2018-532-M-B). In-kind support was provided by Medtronic (HCL systems and technical expertise with device issues). B.P. is supported by a University of Melbourne scholarship and research support from JDRF. D.P.Z. is supported by a Leona M. and Harry B. Helmsley Charitable Trust grant and International Society for Pediatric and Adolescent Diabetes-JDRF research fellowship. M.H.L. is supported by a National Health and Medical Research Council (NHMRC) postgraduate scholarship, cofunded by Diabetes Australia. S.A.M. is supported by a JDRF Early-Career Patient-Oriented Diabetes Research Award (5-ECR-2017-371-A-N). A.J.J. is supported by an NHMRC Fellowship and is a Sydney Medical School Foundation Fellow and received research support from the NHMRC of Australia, JDRF Australia, and JDRF International. R.J.M. received research grants from the Rebecca L. Cooper Medical Research Foundation, St Vincent’s Foundation, JDRF, Diabetes Australia Research Trust/Program, and the NHMRC of Australia.

JDRF Australia provided input into the trial design. The funders of the trial had no role in data collection, data analysis, data interpretation, or writing of the report.

Duality of Interest. B.P. and M.H.L. report speaker honoraria fees from Medtronic. D.P.Z. has received speaker honoraria fees from Medtronic Diabetes, Ascensia Diabetes, and Insulet. S.A.M. has served on a Medtronic advisory panel and received speaker honoraria from Eli Lilly and Company, Roche, and Sanofi. R.J.M. reports research grants from Novo Nordisk, Servier, Medtronic, and Grey Innovation; received honoraria for lectures from Eli Lilly and Company, Novo Nordisk, Sanofi, AstraZeneca, Merck Sharp & Dohme, Novartis, and Boehringer Ingelheim; received travel support from Novo Nordisk, Sanofi, and Boehringer Ingelheim; is on the advisory boards for Novo Nordisk, Sanofi, Boehringer Ingelheim, Lilly Diabetes Alliance, and AstraZeneca; and has been a principal investigator for industry-sponsored clinical trials run by Novo Nordisk, Bayer, Janssen-Cilag, and AbbVie Inc. A.J.J. has received research support from Medtronic, Sanofi, Abbott Laboratories, and Mylan; and has served on advisory boards for Medtronic, Sanofi, and Abbott Diabetes Care. M.C.R. has served on advisory boards for Supersapiens, Zucara Therapeutics, Zealand Pharma, and Indigo Diabetes; and has received speakers honoraria from Medtronic Diabetes, Insulet, Ascensia Diabetes, Novo Nordisk, Xeris Pharmaceuticals, Lilly Diabetes, and Lilly Innovation. D.N.O. has served on advisory boards for Abbott Laboratories, Medtronic, Merck Sharp & Dohme, Novo Nordisk, Roche, and Sanofi; received research support from Medtronic, Novo Nordisk, Roche, Eli Lilly and Company, and Sanofi; and received travel support from Novo Nordisk and Merck Sharp & Dohme. No other potential conflicts of interest relevant to this article were reported.

Author Contributions. B.P., S.A.M., C.E.M.S., M.C.R., B.R.K., and D.N.O. designed the study. B.P., D.M., M.C.R., and D.N.O. led the study. B.P., D.M., D.P.Z., M.H.L., H.J., V.O., S.A.M., M.C.R., and D.N.O. assisted with implementation of the study. B.P. wrote the first draft of the report with input from D.M. and D.N.O. All authors critically reviewed the report. B.P. and S.V. contributed to data analysis. B.P. and D.N.O. are the guarantors of this work and, as such, had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Prior Presentation. This work was presented at the Australasian Diabetes Congress 2021 (Australian Diabetes Society and Australian Diabetes Educators Association Annual Scientific Meeting), 11–13 August 2021.